Clobetasol Propionate NDC 50090-8001

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-8001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-8001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-8001-0	50090800100	1 TUBE in 1 CARTON (50090-8001-0) / 30 g in 1 TUBEMarketed from Jun 18, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clobetasol Propionate
Generic name (nonproprietary): clobetasol propionate
Active ingredients: Clobetasol propionate — .5 mg/g
Dosage form: Ointment
Route: Topical
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215990
Marketing start: Feb 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 50090-8001_0a97beb9-db7c-4b93-be12-d9f8ec3ef810SPL ID 0a97beb9-db7c-4b93-be12-d9f8ec3ef810SPL set ID 8da21ad7-4d2d-4168-82ee-ebf13ce5e923RxCUI 861448UNII 779619577M
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090800100 followed by a unit qualifier and the quantity

Package 50090-8001-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 23, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Clobetasol propionate ointment is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215990

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215990
Product	Strength	Form · route	Labeler	Product NDC
Clobetasol Propionate ANDAclobetasol propionate	Clobetasol propionate .5 mg/g	OintmentTopical	Macleods Pharmaceuticals Limited	33342-506
Clobetasol Propionate	Clobetasol propionate .5 mg/g	OintmentTopical	NorthStar RxLLC	72603-855